RTW Investments Increases Stake to 19.2% in Orchestra BioMed via Warrant Exercise
Summary
RTW Investments, LP and its affiliated funds exercised pre-funded warrants, resulting in the issuance of 1.25 million new shares of Orchestra BioMed Holdings, Inc. common stock and increasing their beneficial ownership to 19.2%.
Key Events
-
Warrant Exercise
RTW Funds exercised pre-funded warrants to acquire 1,250,032 shares of common stock.
-
Share Issuance
1,250,000 new common shares were issued to RTW Funds on a cashless basis, after withholding 32 shares to satisfy the exercise price.
-
Increased Ownership Stake
RTW Investments' beneficial ownership increased to 11,942,394 shares, representing 19.2% of the company's common stock.
-
Dilution Impact
The issuance of new shares results in approximately 2.1% dilution to the outstanding share count.
Analysis
This Schedule 13D/A reports that RTW Investments, a significant institutional investor, converted pre-funded warrants into 1.25 million shares of Orchestra BioMed common stock. While this cashless exercise results in dilution for existing shareholders by increasing the outstanding share count by approximately 2.1%, it also signifies RTW's continued conviction in the company by maintaining a substantial 19.2% beneficial ownership. This event follows the company's recent DEF 14A filing disclosing a $20 million convertible loan from Medtronic, indicating active capital management and ongoing financial activities.
At the time of this filing, OBIO was trading at $3.80 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $222.4M. The 52-week trading range was $2.20 to $5.42. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.